Major Depressive Disorder

28 total trials 15 recruiting

Filter these 28 trials by phase, country, sponsor and more.

Open in Search →

Psilocybin's effects on anhedonia Not authorised

2023-509009-59-00 3
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 5
A randomized controlled trial of the effect of anesthetic dose during electroconvulsive therapy for major depression Pending

2024-519407-99-00 6
Antidepressant effects of psilocybin without the psychedelic serotonin experience: A dimensional approach using functional neuroimaging. Pending

2025-521690-14-00 4
A study for adolescents who are depressed and thinking of suicide Recruiting

2024-518615-19-00 5 2026-04-22
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting

2025-523202-32-00 5 2026-02-26
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 5 2025-10-07
DT-101 in Adults with Major Depressive Disorder Recruiting

2025-522784-15-00 4 2026-03-24
An Open-label Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression Recruiting

2025-524841-28-00 4 2026-03-13
Psilocybin's effects on anhedonia Recruiting

2024-519265-22-00 3 2025-11-12
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 5 2025-10-30
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519420-25-00 5 2025-10-22
Study to assess the maintenance of effect of NBI-1065845 as an adjunctive treatment in participants with Major Depressive Disorder (MDD) Recruiting

2025-520541-72-00 5 2025-10-22
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting

2024-520333-68-00 5 2025-09-26
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519418-29-00 5 2025-09-19
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519421-37-00 5 2025-08-28
A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder Recruiting

2023-503836-41-00 5 2025-03-10
Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression Recruiting

2024-513907-15-01 5 2024-10-11
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for major depressive disorder c … Recruiting

2023-506617-21-00 5 2024-08-29
Trial Examining Methods for Antidepressant Discontinuation (TEMPO) Recruitment ended

2024-511997-66-00 6 2024-11-22
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Recruitment ended

2023-505892-56-00 5 2024-09-30
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit … Recruitment ended

2023-506335-15-00 5 2024-07-18
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a … Ended

2024-513104-34-00 4 2024-11-25
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended

2023-507942-10-00 4 2024-07-31

Showing 1–24 of 28 trials